LOQTORZI (Toripalimab)
Nasopharyngeal Carcinoma (and other undisclosed oncology indications)
ApprovedActive
Key Facts
Indication
Nasopharyngeal Carcinoma (and other undisclosed oncology indications)
Phase
Approved
Status
Active
Company
About TopAlliance Biosciences
TopAlliance Biosciences, founded in 2015 and headquartered in San Diego, is a clinical-stage biopharma developing targeted oncology therapies, most notably antibody-drug conjugates. As the US subsidiary of China's Junshi Biosciences, it benefits from a parent company with a proven track record in antibody development. The company has transitioned to a commercial-stage entity with the US and EU approval of its lead asset, toripalimab (LOQTORZI), for nasopharyngeal carcinoma, and maintains a broader pipeline of novel candidates.
View full company profile